First in Human, Phase I Trial of ZL-1201 in Subjects With Advanced Cancer
Latest Information Update: 24 Aug 2023
At a glance
- Drugs ZL-1201 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ZAI Lab
- 21 Aug 2023 Status changed from active, no longer recruiting to completed.
- 25 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2021 Planned number of patients changed from 65 to 66.